Making sense of the Food and Drug Administration

References 

1. Spurgin EA. Planning effective interaction with FDA. Diabetes Technol Ther. 2004;6(6):770–775
   • MEDLINE
   • CrossRef
2. Kaplan AV, Baim DS, Smith JJ, et al. Medical device development: from prototype to regulatory approval. Circulation. 2004;109:3068–3072
   • CrossRef
3. Maisel WH. Medical device regulation: an introduction for the practicing physician. Ann Intern Med. 2004;140(4):296–302
4. Guidance for industry and FDA staff: premarket assessment of pediatric medical devices. Rockville, MD: U.S. Department of Health and Human Services, Food and Drug Administration; 2004;Available from: http://www.fda.gov/cdrh/mdufma/guidance/1220.html. Accessed April 30, 2006.
5. An overview of FDA: protecting consumers, protecting public health. Rockville, MD: U.S. Department of Health and Human Services, Food and Drug Administration; 2002;Available from: http://www.fda.gov/oc/opacom/fda101/sld001.html. Accessed April 30, 2006.
6. Saviola J. The FDA’s role in medical device clinical studies of human subjects. J Neural Eng. 2005;2:S1–S4
   • MEDLINE
   • CrossRef
7. Rados C. Medical device and radiological health regulations come of age. FDA Consumer. 2006;59–65January/February
8. 21 U.S.C. §321.
9. Kessler L, Richter K. Technology assessment of medical devices at the center for devices and radiological health. Am J Manag Care. 1998;4:SP129–SP135
10. Hackett JL, Gutman SI. Introduction to the Food and Drug Administration (FDA) regulatory process. J Proteome Res. 2005;4(4):1110–1113
    • MEDLINE
    • CrossRef
11. Device classes. Rockville, MD: U.S. Department of Health and Human Services Food and Drug Administration; 2002;Available from: http://www.fda.gov/cdrh/devadvice/3132.html#class_1. Accessed April 30, 2006.
12. 21 U.S.C. §360(c).
13. General controls for medical devices. Rockville, MD: U.S. Department of Health and Human Services, Food and Drug Administration; 2002;Available from: http://www.fda.gov/cdrh/devadvice/363.html. Accessed April 30, 2006.
14. Munzer R. U.S. medical device classification. IEEE Eng Med Biol Mag. 2004;207–298
15. Kaplan AV, Harvey ED, Kuntz RE, et al. Humanitarian use devices/humanitarian use device exemptions in cardiovascular medicine. Circulation. 2005;112:2883–2886
    • CrossRef
16. Rinaldi JE, Chen EA, Berman M. Pediatric circulatory support: an FDA perspective. ASAIO J. 2005;51:533–535
    • MEDLINE
    • CrossRef
17. Listing of CDRH humanitarian device exemption summaries of safety and possible benefit. Rockville, MD: U.S. Department of Health and Human Services, Food and Drug Administration; 1995;Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfHDE/HDEInformation.cfm. Accessed April 30, 2006.
18. McKneally MF, Daar AS. Introducing new technologies: protecting subjects of surgical innovation and research. World J Surg. 2003;27:903–935
19. Caldwell PHY, Murphy SB, Butow PN. Clinical trials in children. Lancet. 2004;364:803–811
    • Abstract
    • Full Text
    • Full-Text PDF (106 KB)
    • CrossRef
20. Steinbrook R. Testing medications in children. N Engl J Med. 2002;347(18):1462–1470
    • CrossRef
21. 21 CFR Part 812.
22. Significant risk and nonsignificant risk medical device studies. Rockville, MD: U.S. Department of Health and Human Services, Food and Drug Administration; 1995;Available from: http://www.fda.gov/cdrh/d861.html. Accessed April 30, 2006.
23. 21 CFR 812.3(i).
24. Determination of intended use for 510(k) Devices: guidance for CDRH staff (update to K98-1). Rockville, MD: U.S. Department of Health and Human Services, Food and Drug Administration; 2002;Available from: http://www.fda.gov/cdrh/ode/guidance/857.pdf. Accessed April 30, 2006.